US-Listed Public Company Profile built from SEC and market records · June 2026

GILEAD SCIENCES, INC. (GILD)

$158.69 +1.70% NASDAQ: GILD · 15-min delayed

FOSTER CITY, California
Public · NASDAQ: GILD
17,000 employees
Founded 1987

Visit website Follow

$160.5BMarket cap

$29.4BRevenue · FY2025

$8.5BNet income

17,000Employees

GILDNASDAQ

1992IPO

About GILEAD SCIENCES, INC.

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Founded: 1987
Type: Public · NASDAQ: GILD
Employees: 17,000
IPO date: Jan 22, 1992
Headquarters: 333 LAKESIDE DR
FOSTER CITY, California 94404
Phone: (650) 574-3000
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: DE, United States
Registered office: Wilmington, US
Legal entity ID: 549300WTZWR07K8MNV44

Source: GLEIF, the global Legal Entity Identifier registry · checked Jul 26, 2026. A US headquarters does not always mean US incorporation.

Is Gilead Sciences, Inc. an American company? Yes. Gilead Sciences, Inc. is incorporated in Delaware, United States and headquartered in Foster City, California. Its legal-entity record reports no foreign parent — the company is independently American-owned.

Registry IDs

Ticker: GILD Nasdaq
SEC CIK: 882095
LEI: 549300WTZWR07K8MNV44
EIN: 943047598
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Gilead Sciences, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/gilead-sciences-inc/"><img src="https://americancompanies.com/badge/gilead-sciences-inc.svg" alt="Gilead Sciences, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow GILEAD SCIENCES, INC. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $29.4B
Net income: $8.5B
Total assets: $59.0B
Market cap: $160.5B

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: GILD

$158.69 +1.70%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$110.56 $158.69

52-week range

Market cap: $160.5B
Dividend yield: 2.07%
Shares outstanding: 1.0B
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Jan 22, 1992

Gilead Sciences, Inc. (GILD) Stock Price

Profitable — net income of $8.5B in FY2025.
Trading near its 52-week high.
Pays a dividend yielding about 2.07% annually.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

Peers & competitors

VE VERTEX PHARMACEUTICALS INC / MAVRTX

PFIZER INCPFE

AbbVie Inc.ABBV

Moderna, Inc.MRNA ME Merck & Co., Inc.MRK

AMGEN INCAMGN

No reviews yet. Be the first to review GILEAD SCIENCES, INC..

Write a review

Newsroom

News about GILEAD SCIENCES, INC.

AC Original Gilead Sciences: A Foster City Drugmaker Built on HIV and Hepatitis C A plain-English look at Gilead Sciences' business, revenue, profit, and market value based on its most recent public fi… Jul 8, 2026

BHC Q3 Earnings Preview: Here's What You Should Know Zacks Investment Research · 2026-10-26 · positive Invesco’s RSPH or iShares’ IBB: Which Healthcare ETF Is the Better Long-Term Buy? The Motley Fool · 2026-10-26 · neutral TG Therapeutics (TGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks Investment Research · 2026-10-26 · neutral How to Find Strong Medical Stocks Slated for Positive Earnings Surprises Zacks Investment Research · 2026-10-26 · positive VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth? The Motley Fool · 2026-10-25 · neutral Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? The Motley Fool · 2026-10-25 · positive

News & sentiment via Polygon.io

FAQ

Gilead Sciences, Inc.: frequently asked questions

Is Gilead Sciences, Inc. an American company?

Yes — Gilead Sciences, Inc. is an American company. Gilead Sciences, Inc. is incorporated in Delaware, United States and headquartered in Foster City, California. Its legal-entity record reports no foreign parent — the company is independently American-owned.

Where is Gilead Sciences, Inc. incorporated?

Gilead Sciences, Inc. is legally incorporated in Delaware, United States, according to its GLEIF legal-entity record.

Who owns Gilead Sciences, Inc.?

Gilead Sciences, Inc. reports no parent company in its legal-entity record — it is independently owned rather than a subsidiary.

Is Gilead Sciences, Inc. traded on a US stock exchange?

Yes — Gilead Sciences, Inc. trades under the ticker GILD on the NASDAQ.

Where is Gilead Sciences, Inc. headquartered?

Gilead Sciences, Inc. is headquartered in Foster City, California, United States.

Is Gilead Sciences, Inc. publicly traded?

Yes — Gilead Sciences, Inc. is a publicly traded company. Its stock trades under the ticker symbol GILD on the NASDAQ.

What does Gilead Sciences, Inc. do?

Gilead Sciences, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.